Pipeline Close ONO PHARMACEUTICAL In 2012, Domain and Ono Pharmaceutical Co., Ltd. (Osaka – Japan) signed a collaboration agreement focused on discovering small molecules targeting G-Protein Coupled Receptors (GPCRs). Domain Therapeutics applied DTect-All™, its proprietary GPCR drug discovery platform and its expertise in GPCR medicinal chemistry and pharmacology to design and optimize small molecules into drug candidates having activity against GPCRs selected by Ono. Ono supported research activities and gained worldwide exclusive rights to develop and commercialize any pharmaceutical product arising out of the drug discovery collaboration. Under the terms of the agreement, Domain was eligible for undisclosed upfront, success-based milestones on the research, development milestones and royalties. Pipeline Partnering Opportunities Resources Careers Contact us 77/100 2021 #Discovermorethanyouthink Strasbourg - Illkirch Domain Therapeutics SA Bioparc 1 - 850 Boulevard Sébastien Brant 67400 Strasbourg - Illkirch - France https://www.domaintherapeutics.com/ Montreal Domain Therapeutics NA Inc. Neomed Institute - 7171 Frédérick Banting H4S 1Z9 Montreal - Canada https://www.domaintherapeutics.ca/ © 2021 Domain Therapeutics - All rights reserved Privacy Legal notices RSS Axeptio consent